ORCID as entered in ROS

Select Publications
2020, 'Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: How effective are they?', in Clinical Dilemmas in Viral Liver Disease Second Edition, pp. 106 - 111, http://dx.doi.org/10.1002/9781119533481.ch18
,2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
,2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
,2010, 'Interferon Alfa', in Kucers' The Use of Antibiotics Sixth Edition, CRC Press, pp. 2959 - 2975, http://dx.doi.org/10.1201/b13787-291
,2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 230 - 253
,2025, 'Effectiveness of periodic incentives on clinic attendance and hepatitis C testing and treatment for people who inject drugs: A five-year retrospective program evaluation', International Journal of Drug Policy, 143, http://dx.doi.org/10.1016/j.drugpo.2025.104868
,2025, 'Editorial - Supporting the best quality science and the rights of people who use drugs regardless of global policy changes: Perspectives from the co-Editors in Chief of the International Journal of Drug Policy', International Journal of Drug Policy, 142, http://dx.doi.org/10.1016/j.drugpo.2025.104836
,2025, 'Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison: a qualitative study', International Journal of Drug Policy, 142, pp. 104831 - 104831, http://dx.doi.org/10.1016/j.drugpo.2025.104831
,2025, 'Professional identities and new technologies of hepatitis C point-of-care testing', Social Science and Medicine, 378, http://dx.doi.org/10.1016/j.socscimed.2025.118140
,2025, 'Sexually transmitted infection prevalence and testing coverage among people who inject drugs: A systematic review', Drug and Alcohol Dependence, 273, http://dx.doi.org/10.1016/j.drugalcdep.2025.112732
,2025, '“It's not just running the test”: Operator experiences of implementing a decentralised hepatitis C point-of-care testing program in Australia', International Journal of Drug Policy, 140, pp. 104800, http://dx.doi.org/10.1016/j.drugpo.2025.104800
,2025, 'The urgent need for implementation science to achieve hepatitis C elimination', Lancet Gastroenterology and Hepatology, 10, pp. 498 - 502, http://dx.doi.org/10.1016/S2468-1253(25)00050-0
,2025, 'A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administration.', J Behav Addict, http://dx.doi.org/10.1556/2006.2025.00033
,2025, 'Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics', Virus Research, 355, http://dx.doi.org/10.1016/j.virusres.2025.199566
,2025, 'Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia', International Journal of Drug Policy, 139, http://dx.doi.org/10.1016/j.drugpo.2025.104790
,2025, 'A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administration', NAD Nordic Studies on Alcohol and Drugs, 42, pp. 107 - 112, http://dx.doi.org/10.1177/14550725251325970
,2025, 'Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis', Lancet Gastroenterology and Hepatology, 10, pp. 315 - 331, http://dx.doi.org/10.1016/S2468-1253(24)00442-4
,2025, 'Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis', Open Forum Infectious Diseases, 12, http://dx.doi.org/10.1093/ofid/ofaf108
,2025, 'Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infection', International Journal of Drug Policy, 137, pp. 104720 - 104720, http://dx.doi.org/10.1016/j.drugpo.2025.104720
,2025, 'A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles', The Lancet Gastroenterology and Hepatology, http://dx.doi.org/10.1016/S2468-1253(25)00069-X
,2025, 'Provider costs of treating opioid dependence with extended-release buprenorphine in Australia', Drug and Alcohol Review, 44, pp. 179 - 194, http://dx.doi.org/10.1111/dar.13956
,2025, 'Missed Opportunities in HCV Care: Trends in Late Diagnosis and Treatment☆', JHEP Reports, pp. 101474 - 101474, http://dx.doi.org/10.1016/j.jhepr.2025.101474
,2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', Lancet Regional Health Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101240
,2024, 'Testing, diagnosis, and treatment following the implementation of a program to provide dried blood spot testing for HIV and hepatitis C infections: the NSW DBS Pilot', BMC Infectious Diseases, 24, http://dx.doi.org/10.1186/s12879-024-08989-8
,2024, 'A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study', Viruses, 16, http://dx.doi.org/10.3390/v16111763
,2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074
,2024, 'Point-of-Care Testing for Hepatitis C Infection: A Critical Building Block for the Foundation to Achieve Elimination', Clinical Infectious Diseases, 79, pp. 974 - 977, http://dx.doi.org/10.1093/cid/ciae156
,2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', Lancet Regional Health Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185
,2024, 'Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis', Lancet Public Health, 9, pp. e684 - e699, http://dx.doi.org/10.1016/S2468-2667(24)00160-9
,2024, 'Understanding hepatitis C virus (HCV) health literacy and educational needs among people in prison to enhance HCV care in prisons', International Journal of Drug Policy, 130, http://dx.doi.org/10.1016/j.drugpo.2024.104516
,2024, 'Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study', International Journal of Drug Policy, 129, http://dx.doi.org/10.1016/j.drugpo.2024.104477
,2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092, http://dx.doi.org/10.1111/dar.13688
,2024, 'The cost-effectiveness of integrating simplified HCV testing into HIV pre-exposure prophylaxis (PrEP) and treatment services among men who have sex with men in Taiwan', Lancet Regional Health Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101119
,2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104468
,2024, 'Patterns of drug use among people who inject drugs: A global systematic review and meta-analysis', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104455
,2024, 'Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis', Eclinicalmedicine, 72, http://dx.doi.org/10.1016/j.eclinm.2024.102596
,2024, 'Where to next for the international journal of drug policy: A continued focus on multidisciplinary research, community involvement, and impact', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104447
,2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390
,2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104394
,2024, 'Health utility among people who regularly use opioids in Australia', Drug and Alcohol Review, 43, pp. 997 - 1012, http://dx.doi.org/10.1111/dar.13823
,2024, 'Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre-exposure prophylaxis in Taiwan: a modelling study', Journal of the International AIDS Society, 27, http://dx.doi.org/10.1002/jia2.26251
,2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028, http://dx.doi.org/10.1111/dar.13828
,2024, 'Vaccination coverage among people who inject drugs: A systematic review', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104382
,2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382, http://dx.doi.org/10.1016/S2468-1253(23)00335-7
,2024, 'Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update', Lancet Gastroenterology and Hepatology, 9, pp. 346 - 365, http://dx.doi.org/10.1016/S2468-1253(23)00321-7
,2024, 'Reply to: “ ‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues”', Journal of Hepatology, 80, pp. e107 - e108, http://dx.doi.org/10.1016/j.jhep.2023.10.020
,2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, pp. ofad637, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2024.104401
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,